Physician profile
Benjamin E Pendergrass
NPI 1396030912
$9,435.41
in general payments reported to CMS, 2019-2025
18 companies · $4,884 in 2025
The $4,884 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $202 · 2021: $780 · 2022: $773 · 2023: $1,276 · 2024: $633 · 2025: $4,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,375 · Food and Beverage: $2,758 · Travel and Lodging: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,375.00 |
| Food and Beverage | $2,757.93 |
| Travel and Lodging | $660.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $4,977.82 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $1,130.43 | 2019-2025 | Precision 1, Total30, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $753.25 | 2019-2025 | Acuvue |
| Glaukos Corporation | $395.98 | 2021-2023 | Kxl System (Not Refurbished) |
| Bausch & Lomb Americas INC. | $381.29 | 2023-2025 | Miebo, Infuse, Xiidra |
| Sun Pharmaceutical Industries INC. | $372.05 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $287.81 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $137.31 | 2019 | |
| Astellas Pharma US INC | $133.56 | 2023 | |
| Dompe US, INC. | $133.49 | 2021-2023 | Oxervate |
| Novartis Pharmaceuticals Corporation | $127.53 | 2019-2022 | |
| Biotissue Holdings INC. | $126.82 | 2023-2025 | |
| Oyster Point Pharma, INC. | $126.04 | 2022-2024 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $105.50 | 2021-2022 | |
| Allergan, INC. | $99.28 | 2019-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $58.61 | 2022-2024 | |
| Aerie Pharmaceuticals, INC. | $45.30 | 2019-2021 | |
| Shire North American Group INC | $43.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Pendergrass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.